Osteoid osteoma and osteoblastoma are bone-forming tumors shown to harbor FOS (87%) and FOSB (3%) rearrangements. The aim was to evaluate the immunohistochemical expression of FOS and FOSB in these tumors in comparison to other bone tumors, to evaluate the influence of decalcification, and to correlate immunohistochemical findings with the underlying genetic alteration using fluorescence in situ hybridization (FISH). Immunohistochemistry using whole sections was performed on osteoid osteoma (n=23), osteoblastoma (n=22), osteoblastoma-like osteosarcoma (n=3), reactive (n=3), and proliferative (n=11) bone lesions. Immunoreactivity in giant cell tumor of bone (n=74), aneurysmal bone cyst (n=6), chondromyxoid fibroma (n=20), osteosarcoma (n=85), chondroblastoma (n=17), and clear cell chondrosarcoma (n=20) was assessed using tissue micro arrays. Strong nuclear expression of FOS in > 50% of the tumor cells was observed in all osteoid osteomas (22/22), in 57% of osteoblastomas (12/21) and in 3/197 control cases. FOS immunoreactivity disappeared after > 3 days decalcification. FOS rearrangements were present in 94% of osteoid osteomas and osteoblastomas, with a concordance of 86% between FISH and immunohistochemistry. Two osteoblastomas (5%) were positive for FOSB, as opposed to 8/177 control cases. Additional FISH revealed no FOSB rearrangements in these cases. To conclude, in short decalcified biopsies, FOS immunohistochemistry can be used to diagnose osteoid osteoma and osteoblastoma, as overexpression is seen in the majority, being rare in their mimics. FOS immunohistochemistry should not be used after long decalcification. Moreover, low level of focal expression found in other lesions and tissues might cause diagnostic problems, in which case FISH could be employed.
Introduction
Osteoid osteoma and osteoblastoma are common boneforming tumors and typically present during the second decade of life. They have no malignant potential, but osteoblastoma can behave locally aggressive [1, 2] . Both lesions are more or less histologically indistinguishable, and distinction is predominantly based on size (diameter below or above 2 cm, respectively) [3] . In addition, osteoid osteomas are usually located in the long bones and present with nocturnal pain relieved by nonsteroidal anti-inflammatory drugs (NSAIDs), while osteoblastomas have a preference for the posterior column of the spine. The most essential feature in osteoid osteoma is the radiographic presence of a central lucent area (nidus), which is surrounded by dense sclerotic bone tissue. In the nidus, regular trabeculae of woven bone are present. These trabeculae are lined by active osteoblasts with vascularized stroma in between. In osteoblastoma, the distribution of woven bone can be slightly less organized, as compared to the nidus of an osteoid osteoma. In the past years, deep sequencing has rapidly advanced the field, as it has provided increased knowledge on the molecular background of bone tumors. Based on these findings, molecular testing as well as specific immunohistochemistry has found its way in routine bone tumor diagnostics that historically heavily relied on morphology and has improved diagnostic accuracy [4, 5] . Recently, recurrent translocations in FOS (87%) and FOSB (3%) were found in osteoblastoma and osteoid osteoma [6] . Both FOS and FOSB are part of the FOS family of transcription factors and were shown to play a role in diverse biological processes, including osteoblast differentiation and proliferation [7] . Also, similar rearrangements are found in vascular tumors [8] [9] [10] [11] . The aim of this study was to evaluate whether the recently found FOS and FOSB rearrangements can be used as an auxiliary diagnostic tool in routine bone tumor diagnosis. We compared immunohistochemistry of FOS and FOSB between osteoid osteoma and osteoblastoma and other lesions with bone deposition. We evaluated the influence of decalcification and, in addition, correlated the immunohistochemical findings to the underlying genetic alteration using interphase fluorescence in situ hybridization (FISH).
Materials and methods

Sample collection
Whole sections were cut from osteoid osteoma (n=23) and osteoblastoma (n=22). All cases were retrieved from the Department of Pathology at Leiden University Medical Center, with the exception of one osteoblastoma. Since samples were collected from routinely processed diagnostic cases, fixation and decalcification time varied. For all internal cases, samples were decalcified in formic acid for a short period of 4 h or longer (range: 2-15 days) until ready for cutting. For the external cases, exact decalcification time and procedure were unknown. The majority (21/23) of osteoid osteoma samples were decalcified shortly, while for osteoblastoma samples, the decalcification time was more variable.
For comparison we included whole sections of proliferative bone lesions (subungual exostosis (n=3), bizarre parosteal osteochondromatous proliferation (BPOP) (n=5), and myositis ossificans (n=3)), samples with reactive callus formation (n=3), and osteoblastoma-like osteosarcoma (n=3). Furthermore, sections of previously constructed tissue micro arrays (TMAs) of giant cell tumor of bone (n=74) [12] , aneurysmal bone cyst (n=6) [12] , chondromyxoid fibroma (n=13) [12] , osteosarcoma (n=76) [12, 13] , chondroblastoma (n=11) [12] , and clear cell chondrosarcoma (n=13) were evaluated [14] . In addition, TMAs of chondroblastoma (n=6) and chondromyxoid fibroma (n=7) and osteosarcoma (n=8) were constructed as described previously [12] . For each sample, three 1.5 mm cores were present on the TMA for representativity. For the osteosarcoma TMA, samples from a previously published cohort were used [15] . For osteosarcoma, both biopsies (n=13) as well as resection specimens were used. As far as could be retrieved, among the osteosarcoma cases, there were samples that were not (n=13) or short (< 3 days, n=19) decalcified.
Decalcification
A decalcification series of placental tissue was taken along with different decalcification periods, ranging from 4 h to 14 days, using a similar protocol as for internal diagnostic samples. Samples were decalcified using 98-100% formic acid (Merck, Kenilworth, New Jersey, USA), diluted 1:5 in demi water with 2.6% sodium formate.
Immunohistochemistry
Immunohistochemistry was performed as described previously with minor adjustments [12] . In brief, microwave antigen retrieval was performed in Tris-EDTA (pH 9.0). A rabbit polyclonal antibody was used against the N-terminal region of FOS (clone, F7799, Sigma, St. Louis, Missouri, USA) and a rabbit monoclonal antibody for FOSB (clone, 5G4, Cell Signaling Technology, Danvers, Massachusetts, USA). Sections for FOS staining were pre-incubated with PBS/1% BSA/5% nonfat dry milk for 30 min at room temperature. Primary antibody was diluted in PBS/1% BSA at 1:200,000 for FOS and at 1:30,000 for FOSB, after which slides were incubated overnight at 4°C. Placenta served as a positive control.
Evaluation of staining
Slides were scored by two observers independently (SWL and JVMGB). Immunoreactivity was scored according to the intensity of the staining (1 = weak, 2 = moderate, or 3 = strong) and the percentage of tumor cells (i.e., the plump osteoblastic cells lining the osteoid or bone) with nuclear staining (1 = 1-25%, 2 = 26-50%, 3 = 51-75%, and 4 = 76-100%) [16] . Positivity was defined as strong nuclear staining in more than 50% of the tumor cells. For the tumors on the TMAs, an average score of 3 cores was used for analysis.
Interphase fluorescence in situ hybridization
For in situ hybridization, BAC probes were used proximal and distal to FOS and FOSB, as described previously [8, 17] . In first instance, a two-color FISH using FOS break-apart and FOSB break-apart was performed on FFPE sections. In case of no signal due to long decalcification, frozen sections were used as an alternative whenever possible. FISH on FFPE slides and on frozen material was performed as described previously [8, 17, 18] . FISH for FOS was performed for all osteoid osteomas and osteoblastomas. In case no FOS rearrangement was present, FISH for FOSB followed. Also, for the immunohistochemically positive control cases, additional FISH was performed. Slides were scored by two observers independently (SWL, KS).
Results
Clinicopathological features of osteoid osteoma and osteoblastoma
Osteoid osteoma and osteoblastoma cases were diagnosed at our institution in a multidisciplinary setting. The average age for osteoid osteoma patients was 22 years (range, 8 to 69 years) and 23 years for osteoblastoma patients (range, 4 to 50 years). In both groups, males were overrepresented (male to female ratio of 3.6:1 and 3.8:1, respectively). For osteoid osteomas, long bones of the lower extremity were affected most (femur, n=9; tibia, n=3), while seven osteoblastomas (30%) were located in the vertebral column.
All osteoid osteoma specimens showed classic morphology and were composed of trabeculae of woven bone. Surrounding osteoblasts were small, with monomorphic oval nuclei and a moderate amount of cytoplasm. Occasionally, few osteoblasts with more abundant eosinophilic cytoplasm were dispersed throughout the specimen. Osteoclast-like giant cells were present in all cases (Fig. 1) . The morphology of osteoblastoma cases was more variable. Three cases showed a clear epithelioid morphology, defined as the presence of numerous large osteoblasts with abundant eosinophilic cytoplasm, in the majority of the specimen. Nuclei were enlarged and were more irregular and hyperchromatic (Fig. 2) . Osteoblastoma was distinguished from osteoblastoma-like osteosarcoma, as the latter demonstrated malignant radiological features and presence of infiltrative growth (Fig. 2) .
Immunohistochemistry of FOS and FOSB
Strong and diffuse nuclear staining for FOS was observed in all osteoid osteomas (22/22) , in 57% of the osteoblastomas (12/21) (Fig. 1) , and in one case with reactive callus formation (1/3). All three osteoblastoma-like osteosarcomas were negative (Fig. 2) . Moderate staining in > 50% of the tumor cells was seen in additional 3 osteoblastomas, 1 (out of 54) conventional osteosarcoma, and 1 (out of 6) aneurysmal bone cyst (Supplementary Table 1 ). Moreover, 45% of the proliferative bone lesions (3/5 BPOP, 1/3 subungual exostosis, and 1/3 myositis ossificans) showed moderate staining in > 50% of the osteoblast-like cells (Fig. 3) . Evaluation of 180 samples on TMAs revealed two positive osteosarcomas, which had an osteoblastic and sclerosing morphology (Fig. 4) . All other tumors did not show strong and diffuse staining (Table 1) . Thus, in total only 3 out of 197 of other bone-forming tumors were positive for FOS immunohistochemistry. The surrounding normal tissues also showed variable moderate to strong nuclear staining, such as endothelial cells and pericytes of mainly larger vessels, striated muscle, chondrocytes, and the epidermis (Supplementary Fig. 1 ). Osteoclasts were completely negative or showed membranous or cytoplasmic staining.
Two of 21 osteoblastomas were FOSB positive (in addition to FOS), while all 22 osteoid osteomas, all 3 osteoblastomalike osteosarcomas, and both cases with reactive callus formation were negative. Five proliferative bone lesions (4/5 BPOP and 1/3 myositis ossificans) showed strong and diffuse nuclear staining. Three out of the 164 TMA samples were positive (osteosarcoma (n=1) and giant cell tumors of bone (n=2)), while the remaining samples were negative (Table 1) . Taken together, 8/177 of other bone-forming tumors were FOSB positive.
Effect of decalcification on FOS and FOSB immunoreactivity
Nuclear staining of decidual cells in placental tissue was moderate to strong in non-decalcified placenta, in short decalcified placenta, and in decalcified placenta up to 3 days. After 3 days, nuclear staining diminished for FOS, turning almost negative after 14 days (Supplementary Fig. 2 ). For FOSB immunohistochemistry, this phenomenon was not observed as after 14 days of decalcification strong nuclear reactivity was retained (Supplementary Fig. 3 ).
Correlation of immunohistochemistry with FISH
Interphase FISH for FOS was performed for all osteoid osteomas and osteoblastomas, which was successful in 31/43 cases (27 paraffin, 4 frozen sections). FOS rearrangements were present in 94% (n=29) of cases, of which 86% (n=25) correlated to strong overexpression of FOS at immunohistochemistry (Table 2) . Four cases were translocation positive, while immunohistochemistry was scored negative; they displayed moderate staining in a variable percentage of cells, which was below the cutoff we used. All four cases were osteoblastomas, of which decalcification time could not be tracked down or varied between 4 h and 2 days.
Two cases lacked FOS rearrangement by FISH, while one of these was immunohistochemically positive (Table 2) . To rule out cross-reactivity of the FOS antibody, additional FISH for FOSB rearrangement was performed, which was negative. After review of H&E slides, clinical records, and radiology, the diagnosis of osteoblastoma remained unchanged ( Supplementary Figs. 4 and 5) . FOS rearrangements were absent in other bone-forming lesions with strong expression of FOS and for which we were able to perform FISH (osteosarcoma (n=1) and reactive bone with callus formation n=1)). Of note, the osteosarcoma sample showed multiple copies of the FOS-locus (Fig. 4) .
In addition, FISH for FOSB was performed in 10 cases with strong immunoreactivity for FOSB. FOSB rearrangements were absent in 5 cases in which FISH was successful (BPOP (n=1), osteosarcoma (n=1), giant cell tumor of bone (n=2), and osteoblastoma (n=1)). Of these, the osteoblastoma case already showed a FOS rearrangement. The osteosarcoma case showed, in addition to multiple copies of the FOS-locus, also multiple copies of the FOSB-locus (Fig. 4) . Both giant cell tumors of bone cases harbored H3F3A p.Gly34Trp mutations shown in a previous study [12] .
Discussion
In this study, we evaluated the utility of the use of immunohistochemistry of FOS to diagnose osteoid osteoma and osteoblastoma. So far this has only been tested in small series, with divergent results, as positivity ranged from 0 (n=11) to 100% (n=3) [6, 19] . Strong overexpression of FOS at immunohistochemistry correlated strongly with the underlying FOS rearrangement. While in a previous study in a minority of cases, FOSB rearrangements were present, instead of FOS rearrangements [6] , we did not find any, rendering FOSB immunohistochemistry diagnostically not relevant. Our study indicates that there are two important caveats that pathologists should be aware of when applying immunohistochemistry for FOS to diagnose osteoid osteoma and osteoblastoma.
First, we showed that after > 3 days of acid-based decalcification, immunoreactivity for FOS disappeared. Though decalcification in EDTA preserves DNA and immunogenicity, acidbased solutions are still commonly used and may affect antigen preservation, leading to loss of sensitivity of immunohistochemistry [20] . In this study, a striking difference between osteoid osteoma and osteoblastoma samples for FOS expression was noticed, as all osteoid osteoma, but only 57% of osteoblastomas showed positivity. In general, osteoid osteoma samples were all small and were decalcified for a short period of only 4 h in most cases, as opposed to osteoblastoma samples. The additional decalcified placental series confirmed diminished nuclear staining after a longer period of decalcification for FOS, while FOSB remained intact. Thus, long decalcification times specifically affect FOS immunohistochemistry, and immunohistochemistry should not be used on resection specimens after prolonged acid-based decalcification.
Second, we scored FOS overexpression as strong and diffuse (> 50% of tumor cells) nuclear expression that we found in all 22 osteoid osteomas and in 12 of 21 osteoblastomas. As could be expected based on their role in normal osteoblast maturation and differentiation [7] , we noticed moderate to strong nuclear positivity for FOS and FOSB in the areas of bone deposition in several reactive and proliferative boneforming lesions. Of the neoplasms, only 1 of 6 aneurysmal bone cysts showed moderate staining in > 50% of the tumor cells, while this was absent in other tumors. This can be a pitfall when using immunohistochemistry, necessitating confirmation by FISH under these circumstances. Partial weak staining was noticed in the majority of other samples and should be considered as not representative of translocationinduced overexpression. Moreover, consistent with previous findings in which copy number gains were noticed in FOS immunopositive osteosarcoma [6] , we also observed FOS positivity in two osteosarcoma samples (osteoblastic and sclerosing subtype). In one case, FISH was possible, which showed gains of FOS and FOSB, potentially resulting in overexpression at immunohistochemistry.
The FOS transcription factor family includes FOS, FOSB, FOSL1, and FOSL2 and encodes leucine zipper proteins that can dimerize with proteins of the JUN family, thereby forming the transcription factor complex AP-1. This way, the FOS proteins regulate a diverse array of biological processes, including cell proliferation, differentiation, and survival. Functional studies have shown that FOS and FOSB, together with other family members of FOS family, are highly expressed during normal osteoblast maturation [21] . Retroviral FOS oncogene can cause osteosarcoma in mouse model systems, when fused with a highly active promoter and the v-fos 3' untranslated region [22] .
Similar rearrangements of FOS and FOSB were previously found in vascular tumors [8] [9] [10] [11] . Identical to FOS-rearranged epithelioid hemangioma, the translocations involve various genes or intergenic regions and lead to a premature stop codon, at or early after the break points that always involve exon 4 of FOS [6, 8] . This causes loss of the C-terminal end of the protein, rendering the protein resistant to degradation causing high expression in tumor cells [23] . The FOSB fusions described in atypical epithelioid hemangioma and pseudomyogenic hemangioendothelioma occur at the Nterminal part of the protein and are most likely induced by promoter swap events, causing upregulation of FOSB [10, 11, 24] .
For bone tumor pathologists, a challenging diagnostic problem is to discriminate epithelioid osteoblastoma from high-grade osteoblastic osteosarcoma. Epithelioid osteoblastomas can be composed of large, plump osteoblasts, surrounded by abundant eosinophilic cytoplasm. Additional degenerative nuclear atypia can be present, accompanied by mitotic figures. Similarly, osteoblastoma-like osteosarcoma can mimic osteoblastoma. Distinction is of crucial importance, as prognosis and treatment differ significantly. While infiltration of host bone and lack of differentiation towards the periphery seem to be the most discriminating features between (epithelioid) osteoblastoma and (osteoblastoma-like) osteosarcoma, this is not often assessable in biopsy and curettage specimens [25, 26] . Although numbers are small, our present results indicate that immunohistochemistry and/or FISH for FOS can be of help in distinguishing (epithelioid) osteoblastoma from osteosarcoma, especially since there are no specific antibodies or molecular tests for osteosarcoma.
To summarize, FOS immunohistochemistry can be used as an auxiliary tool for osteoid osteoma and osteoblastoma in short decalcified tissue, while FOSB immunohistochemistry is diagnostically not useful. However, FOS immunohistochemistry should not be used after long decalcification, and the low-level focal expression found in other lesions and tissues, especially reactive bone, might be confusing. Under these circumstances, the use of FISH for FOS could be diagnostically useful, for cases where it is difficult to distinguish osteoid osteoma and osteoblastoma from their histologic mimics.
Author contributions The study was designed, written, and reviewed by S.W. Lam and J.V.M.G. Bovée. All authors contributed to the data collection, data analysis, and interpretation. The manuscript was approved by all authors.
Compliance with ethical standards
Ethical approval All samples were handled according to the ethical guidelines described in "Code for Proper Secondary Use of Human Tissue in the Netherlands" in a coded (pseudonymized) manner, as approved by the Leiden University Medical Center ethical board (B17.036 and B19.007). 
